◆英語タイトル:Ardelyx Inc (ARDX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8049
◆発行会社(調査会社):
GlobalData
◆発行日:2018年10月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Ardelyx Inc (Ardelyx) is a developer of small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders. The company provides product portfolio such as tenapanor, RDX227675, RDX98940 and RDX013, among others. Its products are used for hyperphosphatemia in patients with end-stage renal disease; constipation-predominant irritable bowel syndrome; and hyperkalemia, in chronic kidney disease patients, among others. Ardelyx develops proprietary drug discovery and design platform to discover and design novel drug candidates such as tenapanor and others. The company works in partnership with pharmaceutical and biotechnology companies to discover small molecule drugs. Ardelyx is headquartered in Fremont, California, the US.
Ardelyx Inc (ARDX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ardelyx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ardelyx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ardelyx Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Knight Therapeutics Enters into Licensing Agreement with Ardelyx 10
Ardelyx Enters into Licensing Agreement with Shanghai Fosun Pharma 11
Kyowa Hakko Kirin Enters into Licensing Agreement with Ardelyx 12
Equity Offering 13
Ardelyx Prices Public Offering of Shares for USD50 Million 13
Ardelyx Raises USD110 Million in Private Placement of Shares 15
Ardelyx Raises USD86.3 Million in Public Offering of Shares 17
Ardelyx Raises USD30 Million in Private Placement of Shares upon Exercise of Warrants 19
Ardelyx Raises Up to USD78 Million in Private Placement of Shares and Warrants 20
Ardelyx Raises USD69 Million in IPO 22
Ardelyx Inc – Key Competitors 24
Ardelyx Inc – Key Employees 25
Ardelyx Inc – Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Financial Announcements 27
Aug 07, 2018: Ardelyx announces second quarter 2018 financial results 27
May 08, 2018: Ardelyx Reports First Quarter 2018 Financial Results and Recent Business Highlights 28
Mar 14, 2018: Ardelyx Reports 2017 Financial Results 29
Nov 07, 2017: Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress 31
Aug 09, 2017: Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results 32
May 05, 2017: Ardelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress 34
Feb 17, 2017: Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results 36
Product News 37
04/18/2017: Ardelyx To Present Tenapanor at Upcoming Spring Medical Meetings 37
Clinical Trials 38
Jan 03, 2018: Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C 38
Nov 21, 2017: Ardelyx Announces Updated Development Path for Tenapanor 39
Oct 16, 2017: Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling 40
Oct 11, 2017: Ardelyxs Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018 41
May 12, 2017: Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C 43
Apr 18, 2017: Ardelyx To Present Poster on TGR5 agonist RDX8940 at Upcoming Spring Medical Meetings 45
Feb 15, 2017: Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease 46
Jan 03, 2017: Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49
List of Tables
Ardelyx Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ardelyx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ardelyx Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Ardelyx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Knight Therapeutics Enters into Licensing Agreement with Ardelyx 10
Ardelyx Enters into Licensing Agreement with Shanghai Fosun Pharma 11
Kyowa Hakko Kirin Enters into Licensing Agreement with Ardelyx 12
Ardelyx Prices Public Offering of Shares for USD50 Million 13
Ardelyx Raises USD110 Million in Private Placement of Shares 15
Ardelyx Raises USD86.3 Million in Public Offering of Shares 17
Ardelyx Raises USD30 Million in Private Placement of Shares upon Exercise of Warrants 19
Ardelyx Raises Up to USD78 Million in Private Placement of Shares and Warrants 20
Ardelyx Raises USD69 Million in IPO 22
Ardelyx Inc, Key Competitors 24
Ardelyx Inc, Key Employees 25
List of Figures
Ardelyx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ardelyx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ardelyx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8